Handelsavisen
prelaunch
Companies Healthcare RAPP.O
RA
RAPP.O NASDAQ Pharmaceuticals

Rapp.O

$40,79
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,9B USD
P/E
EV / Rev
Div yield
Op margin
ROE
-23,0 %
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
$42,78
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

RAPP.O is a pharmaceutical company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.

Business. RAPP.O is a pharmaceutical company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.

Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY13 analysts
13 buy0 hold0 sell
Avg 12m price target56,73

Analyst recommendations

13 analysts · consensus Buy
Buy13
Hold0
Sell0
12-month price target
56,73
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
13 analysts · indicative
Ownership
Capital Research Global Investors
largest disclosed fund holder
Profitability
-23,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning RAPP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RAPP.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    RAPP.O is a pharmaceutical company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a conservative capital structure with zero debt-to-equity ratio and total liabilities of $27.8 million against total assets of $512.4 million. Total equity stands at $484.7 million, providing a substantial buffer. However, liquidity is assessed as low, supported by cash and equivalents of $52.6 million, which may be insufficient given the negative operating cash flow of $87.5 million. The price-to-book ratio is 4.34, indicating the market values the company significantly above its tangible book value despite current unprofitability.

    Profitability metrics are negative, with a return on equity of -23% and return on assets of -21.76%. The company reported an operating income of -$125.1 million and net income of -$111.5 million, reflecting significant pre-commercial or development-stage losses. The EV/EBITDA ratio is negative at -16.38, consistent with companies that have not yet achieved positive earnings before interest, taxes, depreciation, and amortization.

    Segment and geographic revenue data are not available in the provided input, preventing an analysis of revenue concentration or regional exposure. The absence of this data limits the ability to assess diversification risks or specific market dependencies.

    Growth trajectory cannot be determined from the available data as historical revenue and net income trends for the past five years or eight quarters are not provided. The current financial snapshot shows a single period of significant net loss, but without historical context, the direction of growth or decline is unclear.

    Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The primary risk appears to be operational, stemming from the negative cash flow and lack of profitability. The low dilution risk suggests that the company is not currently issuing significant new shares, which is positive for existing shareholders.

    Recent observations include analyst estimates with a mean price target of $56.73 and a median of $56.00, indicating a potential upside from the current market price of $44.00. The mean recommendation is 1.54, with 6 strong buys and 7 buys, suggesting strong analyst confidence in the company's future prospects despite current financial losses. No specific news events or filing observations were detailed beyond the reconciler enqueue triggers.

    Key takeaways
    • The company has a strong balance sheet with zero debt and $484.7 million in equity, but faces liquidity challenges due to negative operating cash flow of $87.5 million.
    • Profitability is negative with ROE of -23% and net income of -$111.5 million, typical for pre-commercial pharmaceutical firms.
    • Analyst sentiment is strongly positive with a mean recommendation of 1.54 and a mean price target of $56.73, implying significant upside from the current $44.00 price.
    • Dilution risk is assessed as low, with no immediate flags for share issuance.
    • Lack of segment, geographic, and historical trend data limits the depth of fundamental analysis.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-07
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $20.0M; Operating income +10,7% YoY.

    Revenue$20.0M
    Operating income-$24.2M+10,7 % YoY
    Net income-$19.9M+17,5 % YoY
    Free cash flow-$19.7M+18,2 % YoY
    EPS
    Operating cash flow-$13.1M+35,5 % YoY
    Financials
    Income statement
    Revenue$20.0M
    Gross profit
    Operating income-$24.2M
    Net income-$19.9M
    Margins
    Gross margin
    Operating margin-121.1%
    Net margin-99.3%
    FCF margin-98.6%
    Balance sheet
    Total assets$497.6M
    Total liabilities$26.1M
    Total equity$471.5M
    Cash & equivalents$78.1M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$13.1M
    CapEx-$86.0k
    Free cash flow-$19.7M
    SBC
    P&L flow · revenue → net income
    Revenue $20.0MOperating costs $44.2MNet income $19.9M
    Highlights
    • Revenue $20.0M
    • Operating income +10,7% YoY
    • Net income +17,5% YoY
    • Free cash flow +18,2% YoY
    • Net margin -99.3%

    Valuation TTM

    Market price
    $40,79
    Market cap
    $2.10B
    Enterprise value
    $2.05B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    4.3x
    P / Tangible book
    4.3x
    Tangible book
    $484.7M
    Net cash
    $52.6M
    Current ratio
    Debt / equity
    ROA
    -21.8%
    ROE
    -23.0%
    Cash conversion
    78.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 33 %
    EPS
    Consensus EPS
    -3,42
    Predicted surprise
    -0,02
    Beat probability
    33 %
    Analysts
    13
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-31 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-3,42
    Revenueno estimateno estimate20,0M USD
    Operating incomeno estimateno estimate-174,8M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution13 analysts
    Strong buy6
    Buy7
    Hold0
    Sell0
    Strong sell0
    12-month price target$56,73 · Median $56,00
    Low $40,00High $80,00
    Operating income · consensus-174,8M USD
    EPS surprise
    +16,3 %
    reported vs consensus · beat
    Revenue surprise
    −100,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$40,00
    Mean$56,73
    Median$56,00
    High$80,00
    Spot$40,79
    +39.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-23,0 %Bottom quartile
    D/E0,00Above P75
    Cash Conv0,78Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 044 600 sh1 exercises · 13 grants13 insiders
    • PEREZ ROBERT JDirector · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
    • Young Wendy B.Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
    • MARAGANORE JOHNDirector · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
    • PAUL STEVEN MDirector · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
    • Silva Paul MDirector · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
    • Sanchez RamiroDirector · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
    • Huber Reid MDirector · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
    • HEALY JAMESDirector · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
    • Bredt DavidChief Scientific Officer · Stock Options (Right to Buy) → Common StockDisposed 6 000 @ $1,80exercise · 2026-02-19
    • Sevigny JeffreyChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 130 000 @ $27,75grant · 2026-02-02
    • Bredt DavidChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 103 000 @ $27,75grant · 2026-02-02
    • Ceesay AbrahamDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 428 000 @ $27,75grant · 2026-02-02
    • Ignelzi Troy A.Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 148 000 @ $27,75grant · 2026-02-02
    • Yeleswaram KrishnaswamyChief Development Officer · Stock Option (Right to Buy) → Common StockAcquired 120 000 @ $27,75grant · 2026-02-02

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • Rapport Therapeutics, Inc. Market data — financials · 2026-07-31
    • reconciler_enqueue (reconciler) on RAPP.O · 2026-07-31
    • Rapport Therapeutics Inc Market data — analyst estimates · 2026-07-31
    • Rapport Therapeutics Inc Market data — ESG · 2026-07-31

    Ownership & reference

    Top holders

    • Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,02 %$97M
    • T. Rowe Price Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$0M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$92M
    • FMR LLCInstitutional Investor · as of 2026-03-310,01 %$224M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,01 %$22M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$7M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$23M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$8M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$7M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$5M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$5M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$24M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$55M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$2M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$2M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$5M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Leadership

    • Abraham N CeesayPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 31 sellsnet -$38,3M5 insiders · last 365d
    • Ceesay AbrahamDirector, Chief Executive Officer · Common StockSold 2 203 @ $42,11$93K · 2026-07-27
    • Ceesay AbrahamDirector, Chief Executive Officer · Common StockSold 7 @ $42,73$299 · 2026-07-27
    • Ceesay AbrahamDirector, Chief Executive Officer · Common StockSold 2 729 @ $40,57$111K · 2026-07-14
    • Ceesay AbrahamDirector, Chief Executive Officer · Common StockSold 5 481 @ $39,72$218K · 2026-07-14
    • Gault CherylChief Operating Officer · Common StockSold 3 792 @ $41,39$157K · 2026-06-30
    • Gault CherylChief Operating Officer · Common StockSold 1 000 @ $43,15$43K · 2026-06-30
    • Gault CherylChief Operating Officer · Common StockSold 3 308 @ $42,17$140K · 2026-06-30
    • Gault CherylChief Operating Officer · Common StockSold 1 900 @ $40,09$76K · 2026-06-30
    • Ceesay AbrahamDirector, Chief Executive Officer · Common StockSold 7 344 @ $39,77$292K · 2026-06-29
    • Ceesay AbrahamDirector, Chief Executive Officer · Common StockSold 876 @ $40,34$35K · 2026-06-29
    • Third Rock Ventures V, L.P.10% owner · Common StockSold 18 572 @ $40,05$744K · 2026-05-26
    • Third Rock Ventures V, L.P.10% owner · Common StockSold 133 618 @ $40,24$5,4M · 2026-05-11
    • Third Rock Ventures V, L.P.10% owner · Common StockSold 5 018 @ $40,31$202K · 2026-05-08
    • Third Rock Ventures V, L.P.10% owner · Common StockSold 271 495 @ $40,12$10,9M · 2026-05-07
    • Third Rock Ventures V, L.P.10% owner · Common StockSold 426 005 @ $40,32$17,2M · 2026-04-17
    • Yeleswaram KrishnaswamyChief Development Officer · Common StockSold 20 225 @ $39,99$809K · 2026-04-17
    • Yeleswaram KrishnaswamyChief Development Officer · Common StockSold 10 200 @ $35,08$358K · 2026-04-14
    • Yeleswaram KrishnaswamyChief Development Officer · Common StockSold 9 165 @ $34,97$321K · 2026-04-13
    • Yeleswaram KrishnaswamyChief Development Officer · Common StockSold 500 @ $34,98$17K · 2026-04-10
    • Yeleswaram KrishnaswamyChief Development Officer · Common StockSold 360 @ $34,90$13K · 2026-04-08
    • Gault CherylChief Operating Officer · Common StockSold 2 839 @ $28,55$81K · 2026-03-30
    • Gault CherylChief Operating Officer · Common StockSold 7 161 @ $28,04$201K · 2026-03-30
    • Yeleswaram KrishnaswamyChief Development Officer · Common StockSold 10 115 @ $29,99$303K · 2026-03-25
    • Gault CherylChief Operating Officer · Common StockSold 2 014 @ $28,93$58K · 2026-03-05
    • Bredt DavidChief Scientific Officer · Common StockOther 6 000 @ $1,80$11K · 2026-02-19

    Short positioning

    2.7Mshares short+19.1% vs prior
    6.13days to cover
    53.0%short of daily vol
    36fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RAPP.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob33 %Surprise-0,02Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 192.2%Derived (calculated)
    • Return on equity (FY 2025-12-31): -23.0%Derived (calculated)
    • Return on assets (FY 2025-12-31): -21.8%Derived (calculated)
    • Current ratio (FY 2025-12-31): 26.17xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.06xDerived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): -74.4%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -7.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 24.3%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 24.3%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -42.4%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -34.9%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -50.6%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 55.6%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 58.7%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 62.7%Derived (calculated)
    • Shares outstanding (annual): 47.77MSEC XBRL filing
    • Total operating expenses (annual): USD 125.1MSEC XBRL filing
    • Operating cash flow (annual): USD -87.47MSEC XBRL filing
    • Total assets (annual): USD 512.43MSEC XBRL filing
    • Operating income (annual): USD -125.1MSEC XBRL filing
    • R&D expense (annual): USD 94.79MSEC XBRL filing
    • Net income (annual): USD -111.48MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -3SEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -3SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-27INSIDERCeesay Abraham sold 2.2k sh — Director, Chief Executive Officer ~$93k
    2026-07-27INSIDERCeesay Abraham sold 7 sh — Director, Chief Executive Officer ~$0k
    2026-07-14INSIDERCeesay Abraham sold 2.7k sh — Director, Chief Executive Officer ~$111k
    2026-07-14INSIDERCeesay Abraham sold 5.5k sh — Director, Chief Executive Officer ~$218k
    2026-06-30INSIDERGault Cheryl sold 3.8k sh — Chief Operating Officer ~$157k
    2026-06-30INSIDERGault Cheryl sold 1.0k sh — Chief Operating Officer ~$43k
    2026-06-30INSIDERGault Cheryl sold 3.3k sh — Chief Operating Officer ~$140k
    2026-06-30INSIDERGault Cheryl sold 1.9k sh — Chief Operating Officer ~$76k
    2026-06-29INSIDERCeesay Abraham sold 7.3k sh — Director, Chief Executive Officer ~$292k
    2026-06-29INSIDERCeesay Abraham sold 876 sh — Director, Chief Executive Officer ~$35k
    2026-06-10 00:00 UTCINSIDER8 insider transactions — 2026-06 8 derivative
    2026-06-10 00:00 UTCINSIDER8 insider transactions — 2026-06 8 derivative
    2026-06-10FILING8-K filing →
    2026-06-10INSIDERHEALY JAMES acquired 15.2k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERMARAGANORE JOHN acquired 15.2k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERPEREZ ROBERT J acquired 15.2k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERPAUL STEVEN M acquired 15.2k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERSilva Paul M acquired 15.2k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERHuber Reid M acquired 15.2k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERYoung Wendy B. acquired 15.2k sh Stock Option (Right to Buy) — Director
    2026-06-10INSIDERSanchez Ramiro acquired 15.2k sh Stock Option (Right to Buy) — Director
    2026-05-26 00:00 UTCINSIDER4 insider transactions — 2026-05 · net sell $17.2M
    2026-05-26 00:00 UTCINSIDER4 insider transactions — 2026-05 · net sell $17.2M
    2026-05-26INSIDERThird Rock Ventures V, L.P. sold 18.6k sh — 10% owner ~$744k
    2026-05-11INSIDERThird Rock Ventures V, L.P. sold 133.6k sh — 10% owner ~$5.38M
    2026-05-08INSIDERThird Rock Ventures V, L.P. sold 5.0k sh — 10% owner ~$202k
    2026-05-07 07:00 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 20.0M · Net USD -19.9M
    2026-05-07FILING10-Q filing →
    2026-05-07FILING8-K filing →
    2026-05-07INSIDERThird Rock Ventures V, L.P. sold 271.5k sh — 10% owner ~$10.89M
    2026-04-23FILINGDEF 14A filing →
    2026-04-21FILING8-K filing →
    2026-04-17 00:00 UTCINSIDER6 insider transactions — 2026-04 · net sell $18.7M
    2026-04-17 00:00 UTCINSIDER6 insider transactions — 2026-04 · net sell $18.7M
    2026-04-17INSIDERThird Rock Ventures V, L.P. sold 426.0k sh — 10% owner ~$17.18M
    2026-04-17INSIDERYeleswaram Krishnaswamy sold 20.2k sh — Chief Development Officer ~$809k
    2026-04-14INSIDERYeleswaram Krishnaswamy sold 10.2k sh — Chief Development Officer ~$358k
    2026-04-13INSIDERYeleswaram Krishnaswamy sold 9.2k sh — Chief Development Officer ~$321k
    2026-04-10INSIDERYeleswaram Krishnaswamy sold 500 sh — Chief Development Officer ~$17k
    Showing the 40 most recent of 70 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage